Facebook
Twitter
LinkedIn
Forward
All Eyes on Evolving Management Strategies for Geographic Atrophy (CME Monograph)
Activity Description and Purpose
Clinicians are presented with unique challenges now that there are new and emerging treatments for geographic atrophy (GA). This educational activity aims to help clinicians recognize epidemiologic factors that influence GA, identify key findings on imaging throughout the course of GA, and understand the pathophysiology of GA in the context of new and emerging treatments. Because the end goal is always to optimize patient care and visual health, there will also be a discussion on incorporating education into patient encounters and the use of low-vision centers. The desired results of this educational activity are for ophthalmologists to enhance patient communication to raise awareness and understanding of GA and its burden and to increase confidence for referral to specialists.
Target Audience
This educational activity is intended for ophthalmologists.
Learning Objectives
After completing this activity, participants will be better able to:
- Recognize factors that influence the epidemiology of geographic atrophy
- Discuss the importance of diagnostic imagery throughout the course of geographic atrophy
- Describe the pathophysiology of geographic atrophy
- Incorporate education on geographic atrophy regularly into patient encounters
Faculty
 | David Eichenbaum, MD (Co-Chair) Collaborative Associate Professor of Ophthalmology Morsani College of Medicine University of South Florida Partner and Director of Research Retina Vitreous Associates of Florida Tampa, Florida |
 | Mark T. Dunbar, OD, FAAO (Co-Chair) Director, Optometric Services Bascom Palmer Eye Institute University of Miami Miller School of Medicine Miami, Florida |
 | Peter K. Kaiser, MD Chaney Family Endowed Chair in Ophthalmology Research Professor of Ophthalmology Cole Eye Institute Cleveland Clinic Lerner College of Medicine Cleveland, Ohio |
 | Michael S. Korenfeld, MD, ACOS President Comprehensive Eye Care, Ltd Washington, Missouri |
Disclosure Policy
MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.
Faculty
Mark T. Dunbar, OD, is a consultant for Allergan, Avellino, Carl Zeiss Meditec, Inc, Iveric Bio, Inc, Orasis Pharmaceuticals, and Visus Therapeutics; and is an advisory board member of Apellis Pharmaceuticals, Genentech, Inc, Regeneron Pharmaceuticals, Inc, and Tarsus Pharmaceuticals, Inc.
David Eichenbaum, MD, is a consultant for Alimera Sciences, Allergan, Apellis Pharmaceuticals, Bausch & Lomb Incorporated, Coherus BioSciences, D.O.R.C. Dutch Ophthalmic Research Center (International) B.V., EyePoint Pharmaceuticals, Genentech, Inc, Gyroscope, Iveric Bio, Inc, KKR, Kodiak Sciences Inc, Novartis Pharmaceuticals Corporation, Opthea, Outlook Therapeutics, Inc, Recens Medical, Inc, Regeneron Pharmaceuticals, Inc, REVIVE2 Biotechnology, Inc, and Vial; is on the speakers bureau for Allergan, Apellis Pharmaceuticals, Bausch & Lomb Incorporated, Bayer Corporation, D.O.R.C. Dutch Ophthalmic Research Center (International) B.V., EyePoint Pharmaceuticals, Genentech, Inc, and Novartis Pharmaceuticals Corporation; is a contracted researcher for 4DMT, Alexion Pharmaceuticals, Inc, Alkahest, Inc, Allegenesis Biotherapeutics Inc, Annexon Inc, AsclepiX Therapeutics, Bayer Corporation, Chengdu Kanghong Pharmaceutical Group Co Ltd*, EyePoint Pharmaceuticals, Gemini Therapeutics, Genentech, Inc, Gyroscope, Ionis Pharmaceuticals, Inc, Iveric Bio, Inc, Kodiak Sciences, Mylan NV*, NGM Biopharmaceuticals, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc, Opthea, Recens Medical, Inc, Regeneron Pharmaceuticals, Inc, and Unity Biotechnology; and has individual stocks or stock options in Clearside Biomedical, Inc, Johnson & Johnson Vision Care, Inc, and REVIVE2 Biotechnology, Inc†.
Peter K. Kaiser, MD, is a consultant for Allegro Ophthalmics, LLC, Allergan, Annexon Inc, Bayer Corporation, Bausch & Lomb Incorporated, Biogen Idec, Iveric Bio, Inc, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc, Regenexbio Inc, Regeneron Pharmaceuticals, Inc, and Stealth BioTherapeutics Inc.
Michael S. Korenfeld, MD, is a consultant for AimMax Therapeutics, EyePoint Pharmaceuticals, Oculis, and Thea Pharmaceuticals Limited; and is an advisory board member of Novartis Pharmaceuticals Corporation.
Peer Reviewer
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners, Managers, and Writers
Carrie Allen, PharmD, BCPP, BCPS, MedEdicus Content Manager for this activity, was previously employed by CVS within the past 2 years, but that relationship has ended.
Medical Writer: Tony Realini, MD, is a consultant for iSTAR Medical*, Ivantis Inc*, New World Medical, Inc, Ocular Therapeutix, Inc, Oyster Point Pharma Inc, and Sight Sciences.
Other MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.
* The financial relationship existed during the past 24 months but has now ended.
† Individual stocks or stock options have not been exercised
Accreditation Statement
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from Iveric Bio, Inc.
Off-Label Discussion
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC, Iveric Bio, Inc, or Review of Ophthalmology.
©2023 MedEdicus LLC. 291
Available Credit
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Participation